Cryopreserved Platelets (CPP) for US FDA Licensure
ID: HT9425-25-RFI-PDM-01Type: Sources Sought
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)ARMY MED RES ACQ ACTIVITYFORT DETRICK, MD, 21702, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

Original Source

https://sam.gov/opp/192b183028d34427a87e22a2da7c69e8/view
Timeline
  1. 1
    Posted Jan 14, 2025, 12:00 AM UTC
  2. 2
    Updated Jan 14, 2025, 12:00 AM UTC
  3. 3
    Due Jan 20, 2025, 8:00 PM UTC
Description

The Department of Defense, through the Defense Health Agency (DHA), is seeking input from qualified entities for the development of Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP) aimed at enhancing the shelf life of platelet products for military use. This initiative is part of the U.S. Combat Casualty Care Research Program and focuses on creating a biologic product that can be stored for up to two years, significantly improving upon the current five-day storage limit for liquid stored platelets. The project is critical for ensuring the readiness and quality of life for active-duty personnel, with a low-rate initial production goal of 1,500 units anticipated over a 20-month performance period. Interested parties are encouraged to submit a white paper detailing their capabilities and relevant experience by January 20, 2025, and can contact Peter Mitchell at peter.d.mitchell8.civ@health.mil for further information.

Point(s) of Contact
Peter Mitchell
peter.d.mitchell8.civ@health.mil
Files
Title
Posted
CPP-RFI-Doc.docx
Jan 14, 2025, 6:05 PM UTC
The United States Army Medical Research and Development Command (USAMRDC) issued Request for Information (RFI) HT9425-25-RFI-PDM-01 to seek input on the development of Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets (CPP). This biologic product aims to enhance the shelf life of platelets, extending it to two years compared to the current five-day limit for liquid stored platelets. The RFI outlines the mission to develop medical materials that ensure the readiness of the Warfighter while improving the quality of life for active-duty personnel. The document states that the response is for planning purposes, not a solicitation, and invites interested parties to present their capabilities and approaches to meet FDA standards for manufacturing, storage, and regulatory compliance of CPP. The submission guidelines include providing a white paper and contact information, emphasizing the importance of demonstrating relevant experience and technical capabilities. The anticipated Phase 3 performance period for the CPP initiative is estimated at 20 months, with a low-rate initial production goal of 1,500 units. Submissions are due by January 20, 2025, underscoring the urgency and relevance of collaboration between the government and potential partners in advancing this critical medical product.
Lifecycle
Title
Type
Cryopreserved Platelets (CPP) for US FDA Licensure
Currently viewing
Sources Sought
Similar Opportunities
Pyridostigmine Bromide Tablets
Buyer not available
The Defense Logistics Agency (DLA) Troop Support is seeking sources capable of providing Pyridostigmine Bromide Tablets (PB Tabs), specifically the USP 30 MG formulation, in compliance with FDA specifications. The procurement involves an estimated annual requirement of 27,000 packages, with each package containing 210 individually sealed tablets, and deliveries will be made to the Defense Distribution Center in Norfolk, VA. Pyridostigmine Bromide Tablets are critical for military use, and the contract will include a base year with four one-year option periods, allowing for adjustments based on service requirements. Interested vendors should submit their responses electronically to Contracting Specialist Rosbert Jones at rosbert.jones@dla.mil, ensuring all information remains confidential as per federal regulations.
Duloxetine HCL DR Capsules
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR Capsules, which includes various dosages and packaging options. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in April 2025. Interested parties should direct inquiries to Christopher Newman at christopher.newman@dla.mil or 445-737-7371, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.
Dressing Sponges
Buyer not available
The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is preparing to issue a Sources Sought notification for the establishment of a Qualified Suppliers Listing (QSL) for Dressing Sponges, with an anticipated release date around April 24, 2025. This initiative aims to solicit information and products for evaluation to create a QSL that will support the Medical/Surgical Prime Vendor (MSPV) program, focusing on single-use, sterile and nonsterile dressing sponges made from woven and nonwoven materials, excluding those made with natural rubber latex. Interested vendors must have or be in the process of obtaining a Distribution and Pricing Agreement (DAPA) and ensure compliance with Trade Agreements Act (TAA) requirements, with all relevant details to be made available on the SAM.gov website upon the announcement. For further inquiries, vendors can contact MMESO Enterprise Wide Standardization at dha.detrick.med-log.mbx.mmeso@health.mil or Tara J. Perrien at tara.perrien@dla.mil.
A Human Multi-Organ Tissue Equivalent Platform to Model High Consequence Threat Agents
Buyer not available
The Department of Defense, through the Army Medical Research Acquisition Activity, is seeking a contractor to develop a Human Multi-Organ Tissue Equivalent Platform aimed at modeling high consequence threat agents. This initiative focuses on creating a micro-engineered organ/tissue equivalent platform that will facilitate the modeling of pathogenic outcomes from emerging infectious diseases and the testing of medical countermeasures, particularly for respiratory viruses such as SARS-CoV-2, MERS, and pandemic H1N1 influenza. The project is critical for enhancing the military's capability to protect warfighters from both natural and manmade threats, ensuring rapid identification of effective medical responses. Interested contractors must submit their capabilities by 10:00 AM EST on April 14, 2025, and can direct inquiries to Kirstin L. Quinn at Kirstin.L.Quinn.civ@health.mil.
Specimen Container Peel Pack
Buyer not available
The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking vendors for the Qualified Suppliers Listing (QSL) for Specimen Container Peel Pack products intended for use in Military Treatment Facilities and operational assemblages. Vendors must possess or apply for a Distribution and Pricing Agreement (DAPA) number, maintain active registration with the System for Award Management (SAM), and have agreements with DoD Medical/Surgical Prime Vendors such as Cardinal Health and Owens & Minor. This initiative is crucial for standardizing medical supplies within the Military Health System, ensuring compliance with quality standards and regulations, including the Trade Agreements Act (TAA). Interested vendors should submit their QSL Package Worksheet and supporting documentation by August 1, 2024, and can direct inquiries to Cornelius Brother at cornelius.l.brothers.ctr@health.mil or Moises Soto at moises.soto1.ctr@health.mil.
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Buyer not available
The Department of Defense (DoD) is soliciting quotes for a Blanket Purchase Agreement (BPA) and an Additional Discount Program (ADP) related to pharmaceutical agents under the Uniform Formulary (UF) for the Military Health System (MHS). This procurement aims to establish an effective pharmacy benefits program, ensuring the selection of clinically and cost-effective pharmaceutical agents as mandated by law (10 U.S.C. § 1074g). The upcoming Pharmacy and Therapeutics (P&T) Committee meeting, scheduled for May 7-8, 2025, will review newly approved drugs, with quotes due by April 17, 2025. Interested manufacturers should submit their proposals, including a signed quote and National Drug Code (NDC) price list, to the primary contact, Keith Marasigan, at keith.b.marasigan2.ctr@health.mil, or the secondary contact, Stephanie Erpelding, at stephanie.j.erpelding.civ@health.mil.
Ambr 250 High Throughput Bioreactor System
Buyer not available
The Department of Defense, through the Defense Health Agency, is seeking to procure an Ambr 250 High Throughput Bioreactor System for the Pilot Bioproduction Facility at the Walter Reed Army Institute of Research in Silver Spring, Maryland. This procurement aims to enhance capabilities for monoclonal antibody production, allowing for simultaneous testing of multiple conditions to accelerate the manufacturing of vaccines and biologics for military-relevant infectious diseases. The system must meet specific Minimum Essential Characteristics, including the ability to process up to 12 cultures, automated controls for critical parameters, and compliance with FDA regulations, particularly 21 CFR Part 11 for data integrity. Interested vendors should note that the anticipated solicitation release is on April 10, 2025, with a contract performance period from June 1, 2025, to May 31, 2029. For further inquiries, contact Ms. Brenda Mena at brenda.i.mena.civ@health.mil or Ms. Sharew Hailu at sharew.hailu.civ@health.mil.
Skin Markers
Buyer not available
The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is preparing to establish a Qualified Suppliers Listing (QSL) for Skin Markers, with a Sources Sought notification anticipated around May 1, 2025. This initiative aims to identify suppliers of sterile and non-sterile skin marking devices that meet stringent medical standards, including the use of non-toxic, biocompatible ink and compliance with Trade Agreements Act regulations. These skin marking devices are essential in medical settings for accurate patient care and procedural documentation. Interested vendors must secure a Distribution and Pricing Agreement (DAPA) and ensure their registration in the System for Award Management (SAM) to participate. For further inquiries, vendors can contact Tara J. Perrien, Contracting Officer, at tara.perrien@dla.mil or the MMESO Enterprise Wide Standardization team at dha.detrick.med-log.mbx.mmeso@health.mil.
Request for Information for Structured Product Labeling (SPL) Document Support for DHA R&D - MRDC - ORA
Buyer not available
The Defense Health Agency (DHA) is seeking information through a Request for Information (RFI) regarding Structured Product Labeling (SPL) document support for its Research & Development Medical Research and Development Command (MRDC). The objective is to assess the feasibility of acquiring commercial solutions that facilitate the submission of SPL documents to the FDA for three licensed New Drug Application (NDA) products requiring labeling changes. This initiative is crucial for ensuring compliance with FDA regulations and maintaining the accuracy of product labeling, which is vital for public health and safety. Interested parties must submit their Capabilities Statements by April 17, 2025, detailing their ability to create, update, and submit SPL documents, along with adherence to technical standards and system validation processes. For further inquiries, respondents can contact Alana M. Sowers at alana.m.sowers.civ@health.mil.
Integrated Power Injection Catheters
Buyer not available
The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is preparing to establish a Qualified Suppliers Listing (QSL) for Integrated Power Injection Catheters, with a presolicitation notice expected to be released around May 15, 2025. This initiative aims to solicit information and products for evaluation, focusing on catheters that are preassembled, sterile, single-use, and disposable, featuring a maximum pressure rating of at least 325 PSI and a passive safety system. These catheters are critical for providing peripheral vascular access for administering fluids, medications, and blood products. Interested vendors must have a Distribution and Pricing Agreement (DAPA) and ensure compliance with Trade Agreements Act (TAA) requirements, with further details to be provided in the upcoming QSL Announcement available on SAM.gov. For inquiries, vendors can contact MMESO Enterprise Wide Standardization at dha.detrick.med-log.mbx.mmeso@health.mil or Tara J. Perrien at tara.perrien@dla.mil.